-
Something wrong with this record ?
Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox"
Z. Moťovská, P. Widimský, R. Petr, D. Bílková, I. Marinov, S. Šimek, P. Kala, Study Investigators PRAGUE-8
Language English Country United States
Document type Randomized Controlled Trial, Research Support, Non-U.S. Gov't
NLK
Journals@Ovid Ovid Full Text
from 2000-01-01 to 2010-02-01
- MeSH
- Aspirin therapeutic use MeSH
- Angioplasty, Balloon, Coronary MeSH
- Diabetes Mellitus, Type 2 complications physiopathology MeSH
- Phosphoproteins metabolism MeSH
- Heparin therapeutic use MeSH
- Hypercholesterolemia epidemiology physiopathology MeSH
- Hypertension complications physiopathology MeSH
- Body Mass Index MeSH
- Platelet Aggregation Inhibitors administration & dosage therapeutic use MeSH
- Drug Therapy, Combination MeSH
- Coronary Angiography MeSH
- Smoking adverse effects MeSH
- Humans MeSH
- Microfilament Proteins metabolism MeSH
- Cell Adhesion Molecules metabolism MeSH
- Coronary Artery Disease drug therapy complications radiography therapy MeSH
- Renal Insufficiency complications physiopathology MeSH
- Aged MeSH
- Sex Factors MeSH
- Hydroxymethylglutaryl-CoA Reductase Inhibitors therapeutic use MeSH
- Ticlopidine analogs & derivatives administration & dosage therapeutic use MeSH
- Age Factors MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
PURPOSE: The aim was to identify factors that influence the efficacy of 600 mg of clopidogrel pretreatment in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. METHODS: In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention. Flow cytometric analysis of the vasodilator-stimulated phosphoprotein phosphorylation state was used. Independent predictors that influenced clopidogrel action were identified using linear regression. RESULTS: There was no correlation between baseline platelet reactivity index (PRI) and severity of coronary atherosclerosis; mean index of platelet reactivity for a nonsignificant lesion was 72% +/- 5.98% and for a significant lesion 70.08% +/- 8.43%. The highest proportion of low responders was patients with diabetes (50% at 28 hours). Among tobacco smokers, the response to clopidogrel occurred quickly and 80% of smokers had effective inhibition of PRI, 12 hours after drug use. After adjustments, tobacco smoking was an independent predictor for the most robust drop of PRI 12 hours after clopidogrel (P = 0.027). The magnitude of total decrease of PRI at 28 hours was not significantly influenced by cigarette smoking (P = 0.12). Linear regression showed that patients on statin therapy had a better response to clopidogrel than those without statins-the mean decrease of PRI at 28 hours was significantly higher (P = 0.02) among these patients (40.0 vs. 27.6). CONCLUSIONS: In stable coronary artery disease, no correlation exists between baseline PRI and the severity and extent of coronary atherosclerosis. A high loading dose of clopidogrel does not satisfactorily suppress enhanced PRI in patients with diabetes. Cigarette smoking is independently associated with a prompt antiplatelet response to clopidogrel. Ongoing statin therapy is an independent determinant of more effective clopidogrel-mediated inhibition of platelet reactivity.
- 000
- 05377naa 2200721 a 4500
- 001
- bmc11019678
- 003
- CZ-PrNML
- 005
- 20121112123319.0
- 008
- 110714s2009 xxu e eng||
- 009
- AR
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Moťovská, Zuzana $7 xx0104795
- 245 10
- $a Factors influencing clopidogrel efficacy in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention: statin's advantage and the smoking "paradox" / $c Z. Moťovská, P. Widimský, R. Petr, D. Bílková, I. Marinov, S. Šimek, P. Kala, Study Investigators PRAGUE-8
- 314 __
- $a Third Medical Faculty, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic. zuzana.motovska@iex.cz
- 520 9_
- $a PURPOSE: The aim was to identify factors that influence the efficacy of 600 mg of clopidogrel pretreatment in patients with stable coronary artery disease undergoing elective percutaneous coronary intervention. METHODS: In a laboratory substudy of the PRAGUE-8 trial, the influences of nonmodifiable (age and sex) and modifiable (body mass index and tobacco smoke) factors, comorbidity (hypertension, hyperlipidemia, diabetes mellitus, and renal insufficiency) and cotherapy (statin, aspirin, and heparin), on the course of clopidogrel efficacy were investigated in 105 patients pretreated with clopidogrel >or=6 hours before coronary angiography +/- percutaneous coronary intervention. Flow cytometric analysis of the vasodilator-stimulated phosphoprotein phosphorylation state was used. Independent predictors that influenced clopidogrel action were identified using linear regression. RESULTS: There was no correlation between baseline platelet reactivity index (PRI) and severity of coronary atherosclerosis; mean index of platelet reactivity for a nonsignificant lesion was 72% +/- 5.98% and for a significant lesion 70.08% +/- 8.43%. The highest proportion of low responders was patients with diabetes (50% at 28 hours). Among tobacco smokers, the response to clopidogrel occurred quickly and 80% of smokers had effective inhibition of PRI, 12 hours after drug use. After adjustments, tobacco smoking was an independent predictor for the most robust drop of PRI 12 hours after clopidogrel (P = 0.027). The magnitude of total decrease of PRI at 28 hours was not significantly influenced by cigarette smoking (P = 0.12). Linear regression showed that patients on statin therapy had a better response to clopidogrel than those without statins-the mean decrease of PRI at 28 hours was significantly higher (P = 0.02) among these patients (40.0 vs. 27.6). CONCLUSIONS: In stable coronary artery disease, no correlation exists between baseline PRI and the severity and extent of coronary atherosclerosis. A high loading dose of clopidogrel does not satisfactorily suppress enhanced PRI in patients with diabetes. Cigarette smoking is independently associated with a prompt antiplatelet response to clopidogrel. Ongoing statin therapy is an independent determinant of more effective clopidogrel-mediated inhibition of platelet reactivity.
- 590 __
- $a bohemika - dle Pubmed
- 650 _2
- $a věkové faktory $7 D000367
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a balónková koronární angioplastika $7 D015906
- 650 _2
- $a Aspirin $x terapeutické užití $7 D001241
- 650 _2
- $a index tělesné hmotnosti $7 D015992
- 650 _2
- $a molekuly buněčné adheze $x metabolismus $7 D015815
- 650 _2
- $a koronární angiografie $7 D017023
- 650 _2
- $a nemoci koronárních tepen $x farmakoterapie $x komplikace $x radiografie $x terapie $7 D003324
- 650 _2
- $a diabetes mellitus 2. typu $x komplikace $x patofyziologie $7 D003924
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a heparin $x terapeutické užití $7 D006493
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a statiny $x terapeutické užití $7 D019161
- 650 _2
- $a hypercholesterolemie $x epidemiologie $x patofyziologie $7 D006937
- 650 _2
- $a hypertenze $x komplikace $x patofyziologie $7 D006973
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikrofilamentové proteiny $x metabolismus $7 D008840
- 650 _2
- $a fosfoproteiny $x metabolismus $7 D010750
- 650 _2
- $a inhibitory agregace trombocytů $x aplikace a dávkování $x terapeutické užití $7 D010975
- 650 _2
- $a renální insuficience $x komplikace $x patofyziologie $7 D051437
- 650 _2
- $a sexuální faktory $7 D012737
- 650 _2
- $a kouření $x škodlivé účinky $7 D012907
- 650 _2
- $a tiklopidin $x analogy a deriváty $x aplikace a dávkování $x terapeutické užití $7 D013988
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Widimský, Petr, $d 1954- $7 jn20000402682
- 700 1_
- $a Petr, Róbert $7 xx0111623
- 700 1#
- $a Mocová, Danuše. $7 xx0193836
- 700 1_
- $a Marinov, Iuri
- 700 1_
- $a Šimek, Stanislav, $d 1963- $7 ola2006345268
- 700 1_
- $a Kala, Petr, $d 1965- $7 xx0043092
- 700 1_
- $a PRAGUE-8, Study Investigators
- 773 0_
- $t Journal of Cardiovascular Pharmacology $w MED00002571 $g Roč. 53, č. 5 (2009), s. 368-372
- 910 __
- $a ABA008 $b x $y 2
- 990 __
- $a 20110715115142 $b ABA008
- 991 __
- $a 20121112123333 $b ABA008
- 999 __
- $a ok $b bmc $g 864506 $s 729557
- BAS __
- $a 3
- BMC __
- $a 2009 $x MED00002571 $b 53 $c 5 $d 368-372 $m Journal of cardiovascular pharmacology $n J Cardiovasc Pharmacol
- LZP __
- $a 2011-3B09/Bjvme